Full-Time
Global healthcare company: wound care, dental
No salary listed
Madrid, Spain
Hybrid
Hybrid role; some on-site work in Madrid is expected.
Bachelor's
See people who can refer or advise you
Solventum provides a wide range of healthcare products across four main areas: wound care and surgical supplies, dental and orthodontic tools, health information software, and purification filters for biopharmaceuticals. These products work by combining material science and data science to help hospitals manage patient records, prevent infections during surgery, and filter fluids for medical treatments like dialysis. Unlike many competitors, the company holds a massive portfolio of over 7,300 patents inherited from its history as a 3M division, allowing it to serve over 75% of U.S. hospitals. Its goal is to use this intellectual property and a disciplined business model to find new solutions for healthcare providers and grow within the global medical technology market.
Company Size
10,001+
Company Stage
IPO
Headquarters
Maplewood, Minnesota
Founded
2023
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Remote Work Options
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Relocation Assistance
Healthcare solutions provider Solventum reported second quarter revenue of $2.21 billion, up 2.2% year on year and ahead of analyst estimates of $2.15 billion. Non-GAAP profit of $2.55 per share beat consensus estimates by 33.8%. The company announced plans to separate its Health Information Systems business to focus on its MedSurg and Dental segments. Management said the move would allow the HIS unit to pursue AI-driven innovation whilst sharpening Solventum's focus as a pure-play MedTech company. Second quarter results were temporarily boosted by approximately $125 million in advanced orders placed ahead of a major ERP system transition, which management expects to reverse next quarter. The company raised its full-year adjusted EPS guidance to $7.15 at the midpoint, a 10% increase. Solventum is nearing completion of its separation from 3M.
Solventum exceeded expectations in Q2, posting $2.2 billion in sales with 9.5% organic growth. However, this included roughly $125 million in advanced ERP-related orders and a $100 million tariff refund. Excluding these benefits, organic growth was approximately 4% and adjusted EPS was estimated at $1.73. The company raised its 2026 outlook, now expecting 2.5%–3% organic sales growth, a 22.2%–22.7% operating margin, adjusted EPS of $7.10–$7.20, and free cash flow of $200 million–$300 million. Third-quarter growth is expected to decline temporarily as the advanced orders reverse. Solventum also announced plans to separate its Health Information Systems business through a potential spin-off or sale, aiming to focus on its MedSurg and Dental segments.
Solventum reported second quarter 2026 sales of $2.2 billion, up 2.2% on a reported basis and 9.5% organically. The MedTech company posted GAAP diluted earnings per share of $0.53 and adjusted diluted EPS of $2.55, marking a 50.9% increase. Operating cash flow reached $227 million, whilst free cash flow totalled $144 million. The strong performance was driven by volume and product mix across all segments, including advance orders ahead of ERP cutovers. Solventum announced plans to separate its Health Information Systems business segment as part of its transformation strategy. The company raised its full-year 2026 guidance, increasing organic sales growth to 2.5% to 3.0%, adjusted EPS to $7.10 to $7.20, and free cash flow to $200 million to $300 million.
Solventum has appointed Neil Zieselman as Senior Vice President, Controller, and Chief Accounting Officer. He will succeed Mary Wilcox, who is retiring. Zieselman brings experience from Surgery Partners, Stryker Corporation, Covanta Holding Corporation, Cendant Corporation, and Avaya. He is a licensed CPA. The company's stock trades at $85.44. It has delivered a 9.5% return over the past week and 19.1% over the past year. For investors, Zieselman's background in healthcare and corporate finance may influence Solventum's financial controls, reporting quality, and regulatory engagement. His approach could shape disclosure practices and capital allocation commentary in future earnings calls. Interest payments are not well covered by earnings, making any changes under the new Chief Accounting Officer particularly important for risk assessment.
Solventum, a healthcare company spun off from 3M Company, has underperformed the broader healthcare sector over the past year despite recent gains. The stock trades 14.5% below its 52-week high of $88.20 reached in December 2025. Whilst SOLV shares climbed 12.4% over the past three months compared to the State Street Health Care Select Sector SPDR ETF's 1.5% gain, the longer-term picture shows divergence. Over 52 weeks, Solventum gained 3.9% whilst the healthcare ETF advanced 12.1%. Year-to-date, SOLV has fallen 4.8% versus the sector's 3.5% decline. The company beat Q1 FY2026 expectations on 5 May, with revenue of $2.01 billion and adjusted EPS of $1.48. Management expects nearly 20 new product launches over two years.